The treatment of osteoporosis represents a large market that is dominated by the bisphosphonate drug class. Although more-efficacious therapies are available, step therapy is commonplace, with these therapies usually relegated to later lines because of their higher prices, duration restrictions, and/or injectable mode of delivery. Additionally, osteoporosis diagnosis and compliance rates are low mainly because of patients’ concern about rare but serious side effects of medications, the asymptomatic nature of the disease, and a limited understanding of the seriousness of osteoporosis. However, despite these obstacles, select branded therapies have achieved significant sales. Opportunities exist for emerging agents in osteoporosis, but these agents will likely face challenges.
QUESTIONS ANSWERED
Scope